Ginkgo Bioworks Holdings (DNA) Income from Non-Controlling Interests (2020 - 2022)
Ginkgo Bioworks Holdings' (DNA) quarterly Income from Non-Controlling Interests came in at $2.4 million in Q4 2022, up 155.08% on a YoY basis from $936954.3 in Q4 2021, and up 236.96% quarter-over-quarter from -$1.7 million in Q2 2022.
Analysis
Ginkgo Bioworks Holdings (DNA) Income from Non-Controlling Interests (2020 - 2022) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has reported Income from Non-Controlling Interests for 3 consecutive years, with $2.4 million the latest figure, recorded in Q4 2022.
- For the quarter ending Q4 2022, Income from Non-Controlling Interests rose 155.08% year-over-year to $2.4 million; the trailing twelve-month figure through Sep 2023 stood at $2.4 million (up 129.25% YoY), and the FY2022 full-year result was -$1.4 million, up 78.12% from the prior year.
- Income from Non-Controlling Interests advanced to $2.4 million in Q4 2022 per DNA's latest filing, from -$1.7 million in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $2.4 million in Q4 2022 and bottomed at -$4.3 million in Q4 2021.
- Historically, Income from Non-Controlling Interests has averaged -$968888.9 across 3 years, with a median of -$753000.0 in 2020.
- The sharpest annual moves came in 2021 and 2022: Income from Non-Controlling Interests plunged 838.03% in 2021, then soared 155.08% in 2022.
- Over 3 years, Income from Non-Controlling Interests stood at -$753000.0 in 2020, then sank by 476.23% to -$4.3 million in 2021, then jumped by 155.08% to $2.4 million in 2022.
- According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered $2.4 million, -$1.7 million, and -$2.1 million for Q4 2022, Q2 2022, and Q1 2022 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.06 Bn | 42.11 Bn | 1.44 Bn | 2.00 Mn |
| 2 | Medpace Holdings | 16.50 Bn | 16.00 Bn | 201.64 Mn | - |
| 3 | Charles River Laboratories International | 13.77 Bn | 13.62 Bn | 452.07 Mn | 722,000.00 |
| 4 | Icon | 12.62 Bn | 11.69 Bn | 479.29 Mn | 19.44 Mn |
| 5 | Fortrea Holdings | 1.68 Bn | 1.51 Bn | 139.20 Mn | - |
| 6 | Evotec SE | 661.34 Mn | 235.46 Mn | - | - |
| 7 | Ginkgo Bioworks Holdings | 442.79 Mn | 358.26 Mn | 18.44 Mn | - |
| 8 | Champions Oncology | 72.49 Mn | 72.62 Mn | 7.03 Mn | - |
| 9 | MindWalk Holdings | 61.66 Mn | 53.38 Mn | 1.82 Mn | - |
| 10 | VivoSim Labs | 1.47 Mn | 1.47 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | 2.39 Mn |
| Jun 30, 2022 | -1.75 Mn |
| Mar 31, 2022 | -2.09 Mn |
| Dec 31, 2021 | -4.34 Mn |
| Sep 30, 2021 | -524,000.00 |
| Jun 30, 2021 | -523,000.00 |
| Mar 31, 2021 | -1.21 Mn |
| Dec 31, 2020 | -753,000.00 |
| Sep 30, 2020 | 71,000.00 |